The company is set to disrupt the existing pharmaceutical market as it executes its global expansion during the coming months.
The world’s nutraceuticals market is set to grow exponentially during the coming years and MedTate is committed to establishing itself as a leading player in this profitable market.
According to a report by Envision Intelligence, the global market is estimated to reach $302,306 million by 2025, at a compound average growth rate of 7.04% during 2019 to 2025.
Existing pharma companies generally try to monetise their R&D in drug development by launching their products as drugs first at high prices and then, only after their patent has expired, do they deliver into the over the counter (OTC) market.
MedTate’s core focus is to bring to market quickly breakthrough and evidence based natural supplements and nutraceuticals.
It uses independent clinically validated research into its products, ensuring Medtate products go straight to the OTC market first so that retail customers can take advantage of ground breaking treatments in supplement form as soon as possible.
The current nutraceutical market is awash with a multitude of generic supplements with little or no evidence base to prove efficacy.
MedTate’s solid two-pronged approach encompasses both R&D and OTC products and ensures the company can introduce clinically validated breakthrough products to market while simultaneously researching and developing these same products into potential prescription medicines.
All of the company’s supplements undergo scientific trials to prove their safety and the ingredients used are based principally on the findings of systematic research. To develop revolutionary products MedTate applies a clinical scientific approach to herbs used in established healing philosophies.
The company was founded in 2011 by entrepreneur Pete Tate. Tate set up the business to bring to market the company’s flagship product - Ojamin - which has been clinically proven to help repair liver cells damaged by fatty liver disease and help counteract the side effects of type 2 diabetes.
The company has road mapped nine other product lines to be introduced during the next 5 years as it continues its global expansion.
With its Ojamin product and its four variants present in 250 top UK pharmacies and health stores, including Selfridges and John Bell & Croydon, the company is set expand globally into 20 new markets within the next 3 years and open R&D centres across Europe, Middle East and Asia.
MedTate is currently undertaking development activities towards drug development in conjunction with top-tier universities in the UK.
